Israel's Rosetta Genomics Ltd. To Raise Up To $39 Million In IPO
Published: Sep 07, 2006
C.E. Unterberg, Towbin, LLC is acting as the lead manager and the sole bookrunner for this offering. Oppenheimer & Co. Inc. and Maxim Group LLC are co-managers for this offering.
Copies of the written preliminary prospectus related to the offering may be obtained from C.E. Unterberg, Towbin's syndicate department at 350 Madison Avenue, 10th Floor, New York, New York 10017 (telephone: +1(212)-389-8056).
A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.
About Rosetta Genomics
Rosetta Genomics is seeking to develop and commercialize new diagnostic and therapeutic products based on a recently discovered group of genes known as microRNAs, which are believed to play an important role in regulating protein production. Rosetta has developed an early and strong intellectual property position related to the development and commercialization of microRNA-based products. Rosetta's current programs are focused on the development of microRNA-based diagnostic and therapeutic products for various cancers and infectious diseases.
Contact: Media & Investors Ron Kamienchick T: +972-8-948-4785 Ron_Ka@RosettaGenomics.com
Source: Rosetta Genomics Ltd